Drug prices in Latin American countries: the case of rheumatoid arthritis Biosimilars

Mosegui, Gabriela Bittencourt Gonzalez; Antõnanzas, Fernando; Vianna, Cid Manso de Mello; Rojas, Paula.
Adv Rheumatol ; 61: 14, 2021. tab
Artículo en Inglés | LILACS | ID: biblio-1152743

Documentos relacionados

  1. Evaluation of the effects of a generic substitution policy implemented in Chile
  2. Availability of biological cancer drugs under research: registration and price in Brazil, Colombia, and Mexico
  3. One-year direct costs of biological therapy in rheumatoid arthritis and its predictive factors: data from the Moroccan RBSMR registry.
  4. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
  5. Presence of anti-citrullinated protein antibodies and costs and disease activity in early rheumatoid arthritis - a 3-year follow-up.
  6. Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial.
  7. Bringing Humira (Its Price) Down a Peg.
  8. Tocilizumab after a first-line with anti-TNF in rheumatoid arthritis: a cost-consequence analysis in the Italian setting.
  9. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study.
  10. Barriers to accessing biologic treatment for rheumatoid arthritis in Greece: the unseen impact of the fiscal crisis--the Health Outcomes Patient Environment (HOPE) study.